Partner

Articles & Insights / Solid State Science

Solid State Characterisation for Crystalline and Amorphous Ingredients

The chemical identity of an ingredient does not fully describe its physical state. Crystal form, hydration and amorphous content can influence processing and product performance, making solid-state characterisation an important part of selected development programmes.

Stabicon Life Sciences3 min read

Accreditations, approvals & registrations

  • Prequalified by WHO, Geneva

    One of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

  • Accredited by ISO/IEC 17025:2017 (NABL)

  • Approved by FSSAI

  • Approved by CDSCO, India

  • Facility Registered with FDA, Karnataka

  • Registered with DSIR

  • Registered with AYUSH

All articles

What this article helps you consider

  • Identify the relevant solid state question
  • Combine complementary techniques
  • Examine the material in its product context

Identify the relevant solid state question

Polymorphs have the same chemical composition but different crystal structures. Hydrates and solvates contain water or solvent within the solid structure and require related but distinct consideration. Amorphous material lacks the long-range order of a crystal. Pharmaceutical guidance sometimes addresses these forms together for practical control purposes, but the underlying distinctions remain useful.

FDA’s pharmaceutical solid-polymorphism guidance concerns ANDA chemistry and manufacturing information. It provides a regulatory context for assessing relevance to product performance; it should not be described as a requirement that every possible solid form must be routinely tested in every product. R49R11

Combine complementary techniques

X-ray powder diffraction can identify characteristic crystalline patterns and help detect changes in form. Differential scanning calorimetry examines thermal events such as melting, glass transition and crystallisation where detectable. Thermogravimetric analysis helps investigate mass changes associated with heating. Microscopy and spectroscopy can provide additional evidence.

A single thermal event does not always establish a unique form. Events can overlap, and the sample may transform during heating. Similarly, a weak diffraction pattern can reflect low concentration, small crystallites or matrix effects rather than complete amorphous character. The illustration illustrates idealised patterns only; it is not a reference spectrum for any substance.

Explore the scienceSolid State Science
Intensity (arbitrary units)00.631.251.882.5510152025303540 Diffraction angle (2 theta, degrees)

Synthetic signals for no named substance. Not reference patterns; they cannot identify or quantify a real material.

Synthetic diffraction patterns illustrate sharp crystalline peaks and a broader amorphous response. These are not reference patterns and cannot identify or quantify a real material.

Examine the material in its product context

An isolated ingredient can change during milling, wet processing, drying, compression or storage. Water and solvents can promote transformations, while excipients may influence crystallisation or analytical detection. Characterise the state that matters to the finished product rather than relying solely on an incoming-material result.

For a hypothetical tablet containing a low concentration of active ingredient, the excipient pattern may dominate the diffraction result. The method must demonstrate that it can answer the intended question at the actual product concentration. A negative finding below the method’s sensitivity is not proof that a minor form is absent.

Relate form to a measurable consequence

Potential differences include dissolution, apparent solubility, mechanical behaviour and stability. Establish whether a form change affects an attribute that needs control. A detectable transformation does not automatically imply a clinically meaningful problem, while a subtle change can be important if it alters release or process consistency.

An amorphous dispersion may show promising initial dissolution but recrystallise during storage. Assess physical stability alongside chemical stability and performance. Faster release in one laboratory medium does not by itself prove improved human absorption.

Design the investigation to avoid artefacts

Control preparation, grinding, humidity and thermal history. Sample treatment intended to improve measurement can itself change the form. Compare as-received and prepared material when needed, and document storage between sampling and analysis. Retain representative material for follow-up.

A useful study might combine controlled-humidity exposure with diffraction, water determination and dissolution. The experimental design should test a defined mechanism, such as hydration-related conversion, rather than collect unrelated measurements without a decision framework.

Establish controls proportional to relevance

Where a form is important, specify an appropriate material attribute, process control or finished-product test. Methods for identity and quantitative determination of a minor form have different performance needs. Reference materials should be suitably characterised and maintained under conditions that preserve their state.

Stabicon can support the integration of material characterisation with formulation and analytical work, including defining when specialised complementary testing is needed. The objective is to understand which physical-state changes matter and how they can be controlled.

References & further reading

Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.

  1. R49
    FDA ANDAs Pharmaceutical Solid Polymorphism

    Final guidance, July 2007. ANDA chemistry, manufacturing and controls scope.

  2. R11
    ICH Q6A Specifications for Chemical Drug Substances and Products

    FDA guidance page. Pharmaceutical specifications and dosage-form considerations.

  3. R05
    ICH Q14 Analytical Procedure Development

    Final guideline adopted November 2023. Development and lifecycle approaches.

From insight to a defined programme

Bring your next technical question.

Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.

Discuss this topic with Stabicon

Continue reading

Related scientific perspectives.

Stabicon Life Sciences

Science-Led Formulations. Scalable Health Platforms.

Offices

Corporate Office

22, 7th Cross, Jaibharath Nagar, Bengaluru 560 033, Karnataka, India

Research & Development

28, Bommasandra Industrial Area, 4th Phase, Jigani Hobli, Anekal Taluk, Bengaluru 560 099, Karnataka, India

Newsletter

Quarterly briefings on platforms, science & partnerships.

No spam. Request a consent withdrawal at bd@stabicon.com.

Press Kit

Logos, company information & spokesperson details – available from our media team.

Request Press Kit

Accreditations

Prequalified by WHO, GenevaAccredited by ISO/IEC 17025:2017 (NABL)Approved by FSSAIApproved by CDSCO, IndiaFacility Registered with FDA, KarnatakaRegistered with DSIRRegistered with AYUSHOne of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. Product packaging and materials may vary from those shown on our website. We recommend that you do not rely solely on the information presented and that you always read labels, warnings, and directions before using or consuming a product.

© 2026 Stabicon Life Sciences Pvt. Ltd. All rights reserved.

Science-Led Formulations. Scalable Health Platforms.

Admin